Monopar Therapeutics (MNPR) Current Assets (2016 - 2025)

Monopar Therapeutics has disclosed Current Assets across 10 years of filings, most recently posting $140.5 million for Q4 2025.

• Current Assets for Q4 2025 came in at $140.5 million, up 132.97% year-over-year; the trailing twelve-month figure through Dec 2025 was $140.5 million (up 132.97% YoY), and the FY2025 annual result was $140.5 million, up 132.97% from the prior year.
• Current Assets came in at $140.5 million for Q4 2025 at Monopar Therapeutics, down from $144.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $144.1 million in Q3 2025 to a low of $6.1 million in Q3 2024.
• The 5-year median for Current Assets is $17.3 million (2022), against an average of $33.5 million.
• Across the five-year window, Current Assets plunged 44.31% in 2023 and jumped 2273.95% in 2025, its largest moves.
• Monopar Therapeutics' Current Assets stood at $20.5 million in 2021, then tumbled by 35.84% to $13.2 million in 2022, then slumped by 44.31% to $7.3 million in 2023, then soared by 722.24% to $60.3 million in 2024, then jumped by 132.97% to $140.5 million in 2025.
• The last three Current Assets figures came in at $140.5 million (Q4 2025), $144.1 million (Q3 2025), and $53.7 million (Q2 2025), per Business Quant data.